Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2111420 Target Snapshot

Cerebral cortex alpha adrenergic receptor · PROTEIN FAMILY · Bos taurus

35Compounds
6Assays
2Approved Drugs
20.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q28838. Use UniProt Q28838 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q28838 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cerebral cortex alpha adrenergic receptor as ChEMBL target CHEMBL2111420, mapped to UniProt Q28838. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cerebral cortex alpha adrenergic receptor
PROTEIN FAMILY · Bos taurus
As of 2026-09-14
ChEMBL target ID
CHEMBL2111420
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q28838
Alpha-2A adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cerebral cortex alpha adrenergic receptor is the right protein anchor across sources, using UniProt Q28838 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAlpha-2A adrenergic receptor
UniProt AccessionQ28838
Component TypeProtein
Sequence Length468 aa

Alpha-2A adrenergic receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cerebral cortex alpha adrenergic receptor, mapped to UniProt Q28838. ChEMBL maps the protein component as Alpha-2A adrenergic receptor. Sequence length is 468 aa.

Mapped IDQ28838
Review nameCerebral cortex alpha adrenergic receptor
OrganismBos taurus
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC5020.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL13644 8.7 IC50 2.0 Preclinical
CHEMBL13645 8.52 IC50 3.0 Preclinical
CHEMBL544428 8.22 IC50 6.0 Preclinical
CHEMBL333794 8.15 IC50 7.0 Preclinical
CHEMBL330997 7.57 IC50 27.0 Preclinical
CHEMBL333795 7.51 IC50 31.0 Preclinical
CHEMBL531 7.39 IC50 41.0 Approved
CHEMBL332337 7.34 IC50 46.0 Preclinical
CHEMBL121653 7.26 IC50 55.0 Preclinical
CHEMBL332546 6.69 IC50 206.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
1
5.5
2
6.0
2
6.5
5
7.0
4
7.5
2
8.0
4
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PERGOLIDE
CHEMBL531
Approved 1988
BROMOCRIPTINE
CHEMBL493
Approved 1978
Assay Landscape

Assay Landscape

6
Total Assays
14
Tested Compounds
1
Assay Types
Binding — 6 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 3 8.4
protein format 2 3 6.6
tissue-based format 2 8 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine